Lund, Sweden – 14 December 2015 — Camurus (NASDAQ STO: CAMX) today announces the appointment of Richard Jameson to the position of Chief Commercial Officer and member of the Executive Management Team, thereby completing the recruitment process informed in the IPO and listing prospectus. Mr. Jameson will assume his position with Camurus during 2016, on a date to be confirmed. Richard Jameson has broad experience from different commercial roles across a number of specialty pharmaceutical companies, including Schering Plough, Ferring and Indivior, where for the last three years he has been serving as Area Director EMEA. In this role he was responsible for the leadership of a commercial organization across Europe, the Middle-East and Africa, focusing on the opioid dependence therapeutic area.
“It is a great pleasure to welcome Richard Jameson to join Camurus. Richard will bring a wealth of experience to our team at a time when we are expanding our business and starting the build-up of our commercial organization in Europe” said Fredrik Tiberg, President and CEO, Camurus.
About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information:
Fredrik Tiberg, CEO and Head of Research
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com
The information in this press release is disclosed by Camurus AB in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.00 a.m. on 14 December 2015.